StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective for the company.

Lipocine Price Performance

Shares of NASDAQ:LPCN opened at $5.10 on Friday. Lipocine has a fifty-two week low of $2.40 and a fifty-two week high of $11.79. The business has a 50-day moving average of $5.10 and a two-hundred day moving average of $5.57. The stock has a market capitalization of $27.29 million, a P/E ratio of -6.71 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, research analysts expect that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.